irinotecan sucrosofate: Clinical Trials

15 trials of irinotecan sucrosofate, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 not yet recruiting, 3 recruiting, 1 active not recruiting. 15 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 315Completed 6, Not yet recruiting 4, Recruiting 3, Active not recruiting 1, Withdrawn 1
Phase 22Not yet recruiting 1, Withdrawn 1

Follow irinotecan sucrosofate: new trials by email Literature Review of irinotecan sucrosofate trials Research Report on irinotecan sucrosofate

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy
Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil - Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3Not yet recruitingMediLink Therapeutics (Suzhou) Co., Ltd.3202026-10-012026-09-04
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab - Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan
Phase 2 / Phase 3Not yet recruitingHebei Medical University Fourth Hospital4082026-05-202026-05-13
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 3RecruitingSWOG Cancer Research Network942026-05-132026-05-22
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Setidegrasib, Oxaliplatin, Leucovorin - Pancreatic Cancer, Metastatic Pancreatic Cancer
Phase 3RecruitingAstellas Pharma Global Development, Inc.6142026-02-172026-11-03
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
Phase 3RecruitingNRG Oncology3562025-08-212026-08-25
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
RMC-6236, Gemcitabine, nab-paclitaxel - Pancreatic Cancer, PDAC
Phase 3Active not recruitingRevolution Medicines, Inc.5002024-10-162026-06-02
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
Liposomal Irinotecan, Oxaliplatin, S-1 - Pancreatic Cancer
Phase 3Not yet recruitingCSPC Ouyi Pharmaceutical Co., Ltd.4082024-09-012024-08-27
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
liposomal irinotecan, 5-FU, LV - Esophageal Cancer
Phase 3Not yet recruitingRui-hua Xu, MD, PhD3602024-08-012024-07-15
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA - Malignant Tumor of Pancreas Metastatic to Liver
Phase 2 / Phase 3WithdrawnSorrento Therapeutics, Inc.2021-11-012022-04-01
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Irinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil - Metastatic Adenocarcinoma of the Pancreas
Phase 3CompletedIpsen7702020-02-112026-04-20
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
eryaspase, Gemcitabine plus Abraxane, Irinotecan plus 5-FU plus leucovorin - Pancreatic Adenocarcinoma
Phase 3CompletedERYtech Pharma5122018-09-152022-10-18
Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
Irinotecan liposome injection, Topotecan - Small Cell Lung Cancer
Phase 3CompletedIpsen4912018-04-252025-02-19
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Irinotecan Liposomal Injection [Onivyde] - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Phase 3CompletedAIO-Studien-gGmbH1512018-03-312025-04-17
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Oxaliplatin, Irinotecan, Leucovorin - Pancreatic Cancer
Phase 3CompletedStanford University272013-08-142022-10-28
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
MM-398, 5 Fluorouracil, Leucovorin - Metastatic Pancreatic Cancer
Phase 3CompletedMerrimack Pharmaceuticals4172011-11-012016-06-17

Conditions studied

Pancreatic Neoplasms (9)  ·  Colorectal Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Ipsen (2)  ·  AIO-Studien-gGmbH (1)  ·  Astellas Pharma Global Development, Inc. (1)  ·  CSPC Ouyi Pharmaceutical Co., Ltd. (1)  ·  ERYtech Pharma (1)  ·  Hebei Medical University Fourth Hospital (1)  ·  MediLink Therapeutics (Suzhou) Co., Ltd. (1)  ·  Merrimack Pharmaceuticals (1)  ·  NRG Oncology (1)  ·  Revolution Medicines, Inc. (1)  ·  Rui-hua Xu, MD, PhD (1)  ·  SWOG Cancer Research Network (1)  ·  Sorrento Therapeutics, Inc. (1)  ·  Stanford University (1)

Countries

United States (9)  ·  France (6)  ·  Germany (6)  ·  Spain (5)  ·  Brazil (4)  ·  Canada (4)  ·  China (4)  ·  Italy (4)  ·  South Korea (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Hungary (3)  ·  Taiwan (3)  ·  Belgium (2)  ·  Czechia (2)

Top investigators

Daniel T Chang (1)  ·  Eliel Bayever, MD (1)  ·  Manfred P. Lutz, Prof. Dr. (1)  ·  Manuel Hidalgo, MD, PhD (1)  ·  Nina N Sanford (1)  ·  Pascal Hammel, MD, PhD (1)  ·  Rachael A Safyan (1)  ·  Ruihua Xu, Professor (1)  ·  Ying Yan, MD MS (1)

Results publications

PMID 26615328, PMID 30414528, PMID 30654298, PMID 30842038, PMID 31789476, PMID 31856081, PMID 33214082, PMID 35195913, PMID 37708904, PMID 38648575, PMID 40696453, PMID 41087530, PMID 41187298, PMID 42080361, PMID 42223072

NIH funding

2017 (1), 2018 (1), U10CA180868 (1), U10CA180888 (1)